Oxaliplatin (NSC 266046)

Catalog No.S1224 Synonyms: L-OHP, Eloxatin

For research use only.

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Oxaliplatin (NSC 266046) Chemical Structure

CAS No. 61825-94-3

Selleck's Oxaliplatin (NSC 266046) has been cited by 153 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Other DNA/RNA Synthesis Products

Biological Activity

Description Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Caco2 NF;s[HNHfW6ldHnvckBCe3OjeR?= MnXkN|AwOTBywrFOwG0> MYexOuKhcA>? M2HOSGROW09? MnzzZYN1cX[jdHXzJG5z\jJ? M1O0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2  MVvGeY5kfGmxbjDBd5NigQ>? M4DROlMwOTBxM{Cg{txO NIjJbXIyPiCq Ml\ySG1UVw>? NU\GN|VNcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>? M4XmXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2  M3\aTGZ2dmO2aX;uJGF{e2G7 NHi0NYw{OMLizszN NG\qNHkzPCCq MX3EUXNQ NHPZPHhqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGhQNTFuIFHLVlFENCCjbnSgUnFQOQ>? M3exPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
SW620 NV73O|l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33pWlExNTdyIH3nM2w> MmnrNlQwPDhxN{KgbC=> M17FXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MmLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NE[zNFUoRjJ2NkS2N|A2RC:jPh?=
SW480  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHJUGpmPDhiaNMg NFqw[5ZKSzVyPUKwMlghfWdxbVy= MmX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkC2O|UoRjJ2N{KwOlc2RC:jPh?=
HCT116 MVjGeY5kfGmxbjDBd5NigQ>? MmHnNk82KML3TR?= NVjJU4d5OjRxNEigbC=> NIfTb4p{fXCycnXzd4V{KHO3co\peolvKG2UTlGg[ZhxemW|c3nvci=> M4fEcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[xOFEyLz5{NEe2NVQyOTxxYU6=
HT-29 NUDDOYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTweJNCOcLizszN NYDpbY01OC15MjDo M{CyZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MnTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 M2fpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHJNZIyyqEQvF2= NHzOclMxNTd{IHi= NYTSS4lrcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M1H2N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
HUVEC MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Fd2lEPTB;MUGuN|DDqMLzwrCxMlAzKM7:TR?= NEX2coI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO|Q1QCd-MkWzNFc1PDh:L3G+
HEK293 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK0TWM2OD16LkiyxsDDucLiNT61PUDPxE1? M4nGeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HT-29 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml24TWM2OD53MDFOwG0> M2P5dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HCT-116 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\JTWM2OD14LkK0xsDDucLiMj65O{DPxE1? NX3yVW9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
MCF-7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjLfXFKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= NWLVeYtrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
HepG2 M16zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHQWGs{UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN NWHmNIhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
A549 M2HTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSwfWhKSzVyPUWxMlA5yqEEsdMgNVAvQTZizszN MoPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
SGC7901 NIq2VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zsTWlEPTB;MkGuO|PDqMLzwrCzMlA5KM7:TR?= NX;COIZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
COC1 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTR4LkKwxsDDucLiMz6xOEDPxE1? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
HCT116  MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPVVXppPzJiaNMg NWLSXYhGUUN3ME22MlI{yrFyLke1JOK2\y:vTB?= M1G4W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wOlMyLz5{NUO2NFY{OTxxYU6=
SW480 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7zeGM4OiCqwrC= MkTqTWM2OD1zMD63xtEzNjJ4INM1[{9uVA>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV|NkC2N|E9N2F-
MIAPaCa-2 NGDrc4VHfW6ldHnvckBCe3OjeR?= M1XGRlI26oDLwsXN MXyyOE81QCCq NGHiVXpqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> NVTaVXF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
Panc-1 NULGSHV[TnWwY4Tpc44hSXO|YYm= NFTSOYQzPeLCidM1US=> NV3SUYFIOjRxNEigbC=> MnXMbY5lfWOnczDjcIVifmGpZTDv[kBRSVKSLDDjZZNx[XOnLUmsJINie3Cjc3WtPEBidmRiY3HzdIF{\S1|wrC= NWf6UYpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
MIAPaCa-2 Mlm0RZBweHSxc3nzJGF{e2G7 Ml[4NlXjiIoEtV2= MYiyOEBp MX7pcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
Panc-1 Mo\pRZBweHSxc3nzJGF{e2G7 MWOyOgKBkcL3TR?= Ml\NNlQhcA>? MYjpcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
HPDE MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXOyOU82OCEQvF2= Mo\rNlQwPDhiaB?= M2LaSIlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NWPuOGJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
SW1990 MknzR4VtdCCYaXHibYxqfHliQYPzZZk> M1zu[|I2NzVyIN88US=> NHr5VJozPC92ODDo NYnX[4FUcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MlHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2 MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUH6T2pmOjVxNUCg{txO NWHOR4dHOjRxNEigbC=> NYTvXlMzcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
Panc-1 M1fjS2NmdGxiVnnhZoltcXS7IFHzd4F6 Mnj1NlUwPTBizszN NV3LOIk{OjRxNEigbC=> NYOwVYYxcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
A549/CDDP NH7Udo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;pOmQ5UUN3ME2xPE43KMLzIEGuNkDPxE1? M3XRVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1NlQ{Lz5{NU[yOVI1OzxxYU6=
A549 NFfnWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHeze|BKSzVyPUWuPEDDuSByLk[g{txO MoTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
SW480 M2rabmZ2dmO2aX;uJGF{e2G7 Moe3NVDjiIoEtXevcYw> MkHrNlTjiImq NGPPeodmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd2OUSyNEc,OjV5NEm0NlA9N2F-
SW620 MV3GeY5kfGmxbjDBd5NigQ>? NG[0OJcyOOLCidM1[{9udA>? MkG2NlTjiImq M3ewW4VvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?= NX\NfJJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFk1OjBpPkK1O|Q6PDJyPD;hQi=>
SW480 NFq5VVBHfW6ldHnvckBCe3OjeR?= Mn3jNVDjiIoEtXevcYw> NFn6SJUzPOLCiXi= NUPSO21OcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= MmPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
SW620 MonhSpVv[3Srb36gRZN{[Xl? MmPMNVDjiIoEtXevcYw> MUiyOQKBkWh? M2fsXIlv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? NGLIVXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
HT-29 M4DRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDZUllyUUN3ME21MlIzKM7:TR?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O|k9N2F-
SNU-175 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17sbWlEPTB;MT61NUDPxE1? M{DpNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
COLO-320DM NIrtfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTVwM{ig{txO M2HS[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
DLD-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nsZWlEPTB;OD62OUDPxE1? Mm\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
DiFi MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnoc2dKSzVyPUGwMlk2KM7:TR?= M{fQTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
HCT-15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\0[2RKSzVyPUiuOlQh|ryP M{fwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
SCM-1 MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[yZ29KSzVyPUG3MlUh|ryP NETEW4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
TMK-1 M4f0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ{Lk[g{txO MnqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
MKN-45 NFvUXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzjTWM2OD1zND6wJO69VQ>? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
AGS MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPUNWV6UUN3ME2xNE43KM7:TR?= NV;4XWRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFkxPTdpPkK1O|g6ODV5PD;hQi=>
S3 NWT2[nN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vHcGlEPTB;NUOuOUDDuSBzLkWg{txO NIW5VW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwNVAxPyd-MkW4NFExODd:L3G+
SiHa M4\BOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\XOYZKSzVyPUCuPEDDuSByLkGg{txO NIjOPVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwNVAxPyd-MkW4NFExODd:L3G+
HT-29 NGnVOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN3Lk[g{txO M4XYOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MECzNFg2Lz5{NkCwN|A5PTxxYU6=
DLD-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qxVWlEPTB;M{KuNkDPxE1? NYTXVnNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFMxQDVpPkK2NFA{ODh3PD;hQi=>
HT29 M1v2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTDeYpKSzVyPU[zJO69VSEEsTCxPC=> NHuzfIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOFA5PCd-Mk[wNFQxQDR:L3G+
MC38 M1fy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv3WVVKSzVyPUKzJO69VSEEsTCy MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNEC4OEc,OjZyMESwPFQ9N2F-
SW620 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[0TWM2OD1|Lk[4JO69VQ>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
SW480 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzaW3pKSzVyPUKuPFYh|ryP MnyzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
RKO M2WxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\yTWM2OD1zLkKzJO69VQ>? Mlv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
LoVo NETBSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DvNmlEPTB;MT6yJO69VQ>? NETVUnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
KM12 M1TPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH3TWM2OD12LkO3JO69VQ>? NVTUdnJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
HCT116p53- MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnnTWM2OD1zLkC4JO69VQ>? NWDCXFduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
HCT116 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\0TWM2OD1zLkC0JO69VQ>? NYrtUoY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
HCT15 MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwNEOg{txO M17WW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HT29 NVXXd2FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXuRllzUUN3ME2yMlY6KM7:TR?= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
DLD1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLXTWM2OD1{LkCxJO69VQ>? M3L1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
Colo205 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTXOlhKSzVyPUOuN|Mh|ryP MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
BE MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rrTWlEPTB;Mz6zN{DPxE1? NUj1TWF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
CT26  MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWO0JI1O MU[0PEBpyqB? M2Ts[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD0c{A2Oy5{JR?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{CxNkc,OjZzM{ewNVI9N2F-
CT26  MnK2SpVv[3Srb36gRZN{[Xl? MkTjOEBuVQ>? MUS0PEBpyqB? NXfTPWxkcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuczDv[kBifXSxcHjh[5kuemWuYYTl[EBxem:2ZXnud{whe3WlaDDhd{BNSzNvSVmsJGJm[2yrbkGgZY5lKEGWR{W= M33HflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFEzLz5{NkGzO|AyOjxxYU6=
CT26  NHXQWnZHfW6ldHnvckBCe3OjeR?= NXLkUGplPCCvTR?= NUPjbpQzPDhiaNMg M3LlR4lv\HWlZYOgZZV1d3CqYXf5 NFLROno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|AyOid-Mk[xN|cxOTJ:L3G+
SK-OV-3 MV\GeY5kfGmxbjDBd5NigQ>? MmTrOVAh|ryPwrC= M3LKVFQ5KGkEoB?= NYqzVGFTeHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> NFm4RW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
OVCAR-5 NFL1eJZHfW6ldHnvckBCe3OjeR?= NXvhTGNrOjBizszNxsA> M2nLVlI1cA>? MYLwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NUfFV|BqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1 NFzYbHZHfW6ldHnvckBCe3OjeR?= NHXjRo8yOCEQvF5CpC=> NWrNbVM3OjSq MlHPdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= M4DpPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
SK-OV-3 NVvQfZNXTnWwY4Tpc44hSXO|YYm= NX\TOYtFPTBizszN NFHZbYE6PiCq NI\wU2R2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? M1jJcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5 NVPP[FRTTnWwY4Tpc44hSXO|YYm= M13TdlMxKM7:TR?= Mn\KOFhp M2f3bJVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
PA-1 MlTYSpVv[3Srb36gRZN{[Xl? NGLh[|YyOCEQvF5CpC=> M4\YfVQ5cA>? Ml;heZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{ M4K0WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
SK-OV-3 NEfFSlZHfW6ldHnvckBCe3OjeR?= M3LEVFUxKM7:TR?= M2XhV|k3KGh? MX;0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= NEDqeHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
OVCAR-5 M33ZRWZ2dmO2aX;uJGF{e2G7 NFTScJk{OCEQvF2= MYi0PIg> M3n0S5RzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> MmLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
PA-1 NUi2XZJoTnWwY4Tpc44hSXO|YYm= NIfjU2cyOCEQvF5CpC=> MW[yOIg> MUf0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= NFvqVJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
SK-OV-3 MmXlR4VtdCCYaXHibYxqfHliQYPzZZk> MVGwMVExOCEQvF2= MlHINlQwPDhxN{KgbC=> NFPo[oNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M1fVWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5 NF7HVHdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:wMVYxKM7:TR?= NV3YWndDOjRxNEivO|IhcA>? MUPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
PA-1 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1\IbVAuOjBizszN NXnyb2Y3OjRxNEigbC=> NHSwR3hqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3yybVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
HCT116 MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwNEJCpOKyyqByLkCyJO69VQ>? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2OEW5Okc,OjZzNEi1PVY9N2F-
HT29 NX3mR253T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXVTWM2OD1yLki4xsDDucLiMD6yJO69VQ>? NEnWcW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG0PFU6Pid-Mk[xOFg2QTZ:L3G+
SNU-387 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\vVWlEPTB;MkZCpOKyyqB{Lkeg{txO MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
SNU-475 NFrDVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnQPIhKSzVy78{eN|Ah|ryP MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
Hep-G2 M2DidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXNRXE3UUN3ME2xN{4yyqEEsdMgNU43KM7:TR?= Moe4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkC0NlkoRjJ4MU[wOFI6RC:jPh?=
SNU-398 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTZwNdMgxtHDqDFwMTFOwG0> M1\uOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
LoVo  NGfqbWdHfW6ldHnvckBCe3OjeR?= NED3blYyNzVizszN Mk\3NlQwPDhiaB?= M2\E[4lv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= M4rBOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkC4OVI{Lz5{NkKwPFUzOzxxYU6=
HCT116 p53+/+ MVPGeY5kfGmxbjDBd5NigQ>? NFvtR3IyNzVizszN NVHmWmtrOjRxNEigbC=> M33LSIlv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= NInlRW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwPFUzOyd-Mk[yNFg2OjN:L3G+
MDA-MB-231 NEHkb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXxWo5KSzVyPUKzMlEhyrFiMD6xJO69VQ>? NXP1[oFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNVE2QTFpPkK2NlEyPTlzPD;hQi=>
MCF-7 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;XZYRKSzVyPUG1MlQhyrFiMD6zJO69VQ>? MkPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
SK-BR-3 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn5TWM2OD1|MT6wJOKyKDBwMTFOwG0> M3nSTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGxOVkyLz5{NkKxNVU6OTxxYU6=
LoVo MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;pNm5xPDhiaNMg NVWwZnY1UUN3ME25OE45OyEQvF2= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ4OUe1PUc,OjZ{Nkm3OVk9N2F-
HCT116 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXu[XJ2PDhiaNMg MXrJR|UxRTFzLki2JO69VQ>? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ4OUe1PUc,OjZ{Nkm3OVk9N2F-
SW480 NVvrUpBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjPWJE4PDhiaNMg MkXLTWM2OD1zLki3JO69VQ>? M4jGWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O|U6Lz5{NkK2PVc2QTxxYU6=
CaES-17 Mnq4R5l1d3SxeHnjbZR6KEG|c3H5 MXuw5qCUOTZywrFOwG0> MmfLOFjDqGh? NUXhW4tWUUN3ME21MlXDqMLzwrCwMlIh|ryP M2jSRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEe0Olk{Lz5{NkS3OFY6OzxxYU6=
HKESC-2 NWDaNHM{S3m2b4TvfIlkcXS7IFHzd4F6 NY\x[IdSOOLCk{G2NOKh|ryP MXK0POKhcA>? MnfnTWM2OD13LklCpOKyyqByLkWg{txO MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-
Assay
Methods Test Index PMID
Western blot VEGFR-1 / NRP-1 ; p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416) ; p-Src(Y418) / p-FAK(Y861) 18790786 19383922
Immunofluorescence E-cadherin / Vimentin ; ATXN2L / G3BP1 30787271
Growth inhibition assay Cell viability 28339092
In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol (from reference)

Cell Research:

[4]

  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control

Animal Research:

[6]

  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage 2 years 4°C(in the dark) powder
Smiles C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05025826 Not yet recruiting Other: Phycocare|Other: Placebo Metastatic Gastric Cancer Nantes University Hospital|Algosource November 5 2021 Not Applicable
NCT05031975 Not yet recruiting Drug: Irinotecan|Drug: Temozolomide Colorectal Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano November 1 2021 Phase 2
NCT05068531 Not yet recruiting -- Colorectal Cancer Metastatic Centre hospitalier de l''Université de Montréal (CHUM)|Exactis Innovation|Chaire Roger Des Groseillers d''oncologie chirurgicale HBP de l''Université de Montréal|Canexia Health October 2021 --
NCT04158349 Terminated Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah March 22 2021 Phase 1
NCT04944550 Recruiting -- Upper Urinary Tract Urothelial Carcinoma|Nephroureterectomy|Tumor|Xenograft Model Centre Hospitalier Universitaire de Nīmes|INSERM U1194 Institut de Recherche en Cancérologie de Montpellier Campus Val d''Aurelle 34298 Montpellier cedex 5 March 1 2021 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is it ok to dissolve Oxaliplatin in DMSO?

Answer:
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

Tags: buy Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) supplier | purchase Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) cost | Oxaliplatin (NSC 266046) manufacturer | order Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) distributor